

#15C
Dai
2/14/03**ADLER & ASSOCIATES**P.O. BOX 710509
HOUSTON, TEXAS 77271-0509WRITER'S DIRECT DIAL
(713) 270-5391
WRITER'S DIRECT FACS.
(713)-270-5361
E MAIL: BADLER1@houston.rr.comINTELLECTUAL PROPERTY LAW
(PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW)January 17, 2002**FACSIMILE COVER SHEET****FAX RECEIVED**

FEB 12 2003

GROUP 1600PLEASE DELIVER TO: Examiner WehbeCOMPANY: USPTOFACSIMILE NUMBER: (703) 308-4242

NUMBER OF PAGES (COUNTING COVER SHEET): 17

FROM: Benjamin A. Adler

MESSAGE: Please deliver the attached to Examiner Wehbe. Examiner Wehbe, attached is a Response After Final for Adenoviral Vector Encoding Pro Apoptotic Bax Gene and Uses Thereof (USSN 09/393,173; D6163). Thank you.

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of this transmittal, the information contained in this facsimile is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader is not the intended recipient or an employee or agent responsible for delivery, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please immediately notify Dr. Benjamin A. Adler at (713) 270-5391 and promptly return the facsimile. Thank you.

02/14/2003 DJACOBS 00000002 071185 09393173

01 FC:2253

465.00 CH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Curiel <i>et al.</i>	§	ART UNIT: 1632
	§	
FILED: September 9, 1999	§	
	§	EXAMINER:
SERIAL NO.: 09/393,173	§	Wehbe, A.M.S.
	§	
FOR: Adenoviral Vector Encoding Pro-	§	
Apoptotic Bax Gene and Uses	§	DOCKET: D6163
Thereof	§	

RESPONSE AFTER FINAL

Dear Sir:

Responsive to the Final Office Action mailed August 28, 2002, please enter the following amendments and remarks. Reconsideration of this application as amended is respectfully requested.

AMENDMENTS**IN THE CLAIMS:**

Please amend claim 3 as follows:

3. (twice amended) A method of treating an individual having a neoplastic disease, comprising the step of administering to said individual a composition comprising an inducible recombinant adenoviral vector encoding a pro-apoptotic *bax* gene which is placed downstream of a loxP excision cassette and a vector encoding a